Exciting news yesterday as resident company C2i Genomics closed their Series A with $12m in funding! Based in NYC and Israel, they are working on post surgery monitoring of cancer recurrence via liquid biopsy. As described on their website:
"C2i Genomics is the first company to develop post-surgery monitoring of cancer recurrence and progression by analyzing subtle changes in the pattern of the tumor’s DNA. Our liquid biopsy Whole Genome assay and cancer burden score will equip oncologists with vital timely information months to years before current monitoring methods are able to."
Follow along with their journey on Linkedin
Interested in joining the team? They're hiring!
Press:
Comments